The penicillin drug market presents opportunities through innovation in β-lactamase-inhibitor combinations, domestic API initiatives, and demand for narrow-spectrum agents. Growth is driven by rising ...
In the ongoing battle against antibiotic resistance, a new study published in Engineering by Zhuoren Ling’s research team unveils a promising triple combination of antibiotics that significantly ...
Titled "The Triple Combination of Meropenem, Avibactam, and a Metallo-β-Lactamase Inhibitor Optimizes Antibacterial Coverage Against Different β-Lactamase Producers," the research sheds light on a ...
EMBLAVEOTM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused by ...
Extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) have become a critical global public health challenge due to their high resistance to β-lactam antibiotics and association with severe ...
Chengdu Tetrahedral Drug Research Co. Ltd. has synthesized bicyclic derivatives acting as β-lactamase (bacterial) inhibitors reported to be useful for the treatment of bacterial infection.
Panelists discuss how sulopenem etzadroxil/probenecid, approved in October 2024, functions as an oral β-lactam/β-lactamase inhibitor effective against extended-spectrum β-lactamase producers per SURE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results